Mauricio Graber joins the Novo Holdings Advisory Group

Novo Holdings is pleased to announce the appointment of Mauricio Graber to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its investments.

Kasim Kutay, CEO of Novo Holdings, said: “With his extensive background and broad executive experience from the bioindustrial sector, Mauricio brings important know-how to the work of the NAG. I very much look forward to working with Mauricio, as the Novo Holdings team will continue to actively look for investments in industrial biotechnology.”

Since 2018, Mauricio has served as CEO of Chr. Hansen, the global bioscience company developing natural ingredients for the food, nutritional, pharmaceutical and agricultural industries.

In addition to this, Mauricio has three decades of experience from the flavour and ingredients industry. He began his career with The NutraSweet Company in 1989, followed by Tastemaker, where he served as Managing Director for Latin America.

When Tastemaker was acquired by Givaudan S.A. in 1997, Mauricio Graber became Givaudan’s Managing Director for Mexico, Central America and the Caribbean before being promoted to Vice-President for Latin America and member of the Flavour Division management team in 2000. Between 2006 and 2018, he served as President of the company’s Flavour Division and was a member of its Executive Committee.

Mauricio Graber brings valuable insights into the commercialisation of innovative solutions to address global challenges through biology.

Mauricio Graber said: “I feel honoured to be appointed to the Novo Holdings Advisory Group. I look forward to the opportunity of leveraging my expertise and contributing to Novo Holdings’ mission as a leading investor committed to better healthcare and a greener future.”

About Mauricio Graber
Mexican citizen

Board positions
Mauricio serves as a member of the Board of Directors of Bacthera AG, Jungbunzlauer Suisse AG and Barry Callebaut, all in Switzerland.

Career
2018 – 2024     CEO, Chr. Hansen, Denmark

2006 – 2018     President, Flavours Division, Givaudan S.A.

2000- 2006      VP, Latin America and member of the Flavour Division management team, Givaudan S.A.

1997 – 2000     Managing Director, Mexico, Central America and the Caribbean, Givaudan S.A.

1995 – 1997      Managing Director, Latin America, Tastemaker.

1991 – 1994       Regional Head, North Latin America, The NutraSweet Company

1989 – 1991       Business Development Manager, The NutraSweet Company

Education
Mauricio holds a Master of Business Administration from Kellogg Graduate School of Management, Northwestern University, US. He also has a Bachelor of Science in Electronic Engineering, Universidad Autonoma Metropolitana, Mexico.

About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.

As of year-end 2022, Novo Holdings had total assets of EUR 108 billion.
www.novoholdings.dk

About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.
www.novonordiskfonden.dk/en